Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania

被引:144
作者
Ramadhani, Habib O.
Thielman, Nathan M.
Landman, Keren Z.
Ndosi, Evaline M.
Gao, Feng
Kirchherr, Jennifer L.
Shah, Rekha
Shao, Humphrey J.
Morpeth, Susan C.
McNeill, Jonathan D.
Shao, John F.
Bartlett, John A.
Crump, John A.
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27710 USA
[2] Tumaini Univ, Kilimanjaro Christian Med Ctr, Moshi, Tanzania
[3] Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania
[4] Duke Univ, Med Ctr, Dept Med, Human Vaccine Inst, Durham, NC 27710 USA
关键词
D O I
10.1086/522991
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Access to antiretroviral therapy is rapidly expanding in sub-Saharan Africa. Identifying the predictors of incomplete adherence, virologic failure, and antiviral drug resistance is essential to achieving long-term success. Methods. A total of 150 subjects who had received antiretroviral therapy for at least 6 months completed a structured questionnaire and adherence assessment, and plasma human immunodeficiency virus (HIV) RNA levels were measured. Virologic failure was defined as an HIV RNA level >400 copies/mL; for patients with an HIV RNA level >1000 copies/mL, genotypic antiviral drug resistance testing was performed. Predictors were analyzed using bivariable and multivariable logistic regression models. Results. A total of 23 (16%) of 150 subjects reported incomplete adherence. Sacrificing health care for other necessities (adjusted odds ratio [AOR], 19.8 P<.01;) and the proportion of months receiving self-funded treatment (AOR, 23.5; P = .04 were associated with incomplete adherence. Virologic failure was identified in 48 (32%) of 150 subjects and was associated with incomplete adherence (AOR, 3.6; P = .03 and the proportion of months receiving self-funded antiretroviral therapy (AOR, 13.0; P = .02). Disclosure of HIV infection status to family members or others was protective against virologic failure (AOR, 0.10; P = .04) Conclusions. Self-funded treatment was associated with incomplete adherence and virologic failure, and disclosure of HIV infection status was protective against virologic failure. Efforts to provide free antiretroviral therapy and to promote social coping may enhance adherence and reduce rates of virologic failure.
引用
收藏
页码:1492 / 1498
页数:7
相关论文
共 30 条
[1]   Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature [J].
Ammassari, A ;
Trotta, MP ;
Murri, R ;
Castelli, F ;
Narciso, P ;
Noto, P ;
Vecchiet, J ;
D'Arminio Monforte, A ;
Wu, AW ;
Antinori, A .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 :S123-S127
[2]  
Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2
[3]   Adherence to HIV antiretroviral therapy in HIV plus Ugandan patients purchasing therapy [J].
Byakika-Tusiime, J ;
Oyugi, JH ;
Tumwikirize, WA ;
Katabira, ET ;
Mugyenyi, PN ;
Bangsberg, DR .
INTERNATIONAL JOURNAL OF STD & AIDS, 2005, 16 (01) :38-41
[4]   Detection of minor drug-resistant populations by parallel allele-specific sequencing [J].
Cai, Fangping ;
Chen, Haifeng ;
Hicks, Charles B. ;
Bartlett, John A. ;
Zhu, Jun ;
Gao, Feng .
NATURE METHODS, 2007, 4 (02) :123-126
[5]   Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort [J].
Calmy, Alexandra ;
Pinoges, Lorextu ;
Szumilin, Elisabeth ;
Zachariah, Rony ;
Ford, Nathan ;
Ferradini, Laurent .
AIDS, 2006, 20 (08) :1163-1169
[6]   Factors associated with nonadherence to highly active antiretroviral therapy -: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase [J].
Carrieri, MP ;
Leport, C ;
Protopopescu, C ;
Cassuto, JP ;
Bouvet, E ;
Peyramond, D ;
Raffi, F ;
Moatti, JP ;
Chêne, G ;
Spire, B .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (04) :477-485
[7]   Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment [J].
Ferradini, L ;
Jeannin, A ;
Pinoges, L ;
Izopet, J ;
Odhiambo, D ;
Mankhambo, L ;
Karungi, G ;
Szumilin, E ;
Balandine, S ;
Fedida, G ;
Carrieri, MP ;
Spire, B ;
Ford, N ;
Tassie, JM ;
Guerin, PI ;
Brasher, C .
LANCET, 2006, 367 (9519) :1335-1342
[8]   Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine - A preliminary report on the Nigerian antiretroviral program [J].
Idigbe, EO ;
Adewole, TA ;
Eisen, G ;
Kanki, P ;
Odunukwe, NN ;
Onwujekwe, DI ;
Audu, RA ;
Araoyinbo, ID ;
Onyewuche, JI ;
Salu, OB ;
Adedoyin, JA ;
Musa, AZ .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (01) :65-69
[9]  
*INDEPTH, 2005, MEAS HLTH EQ SMALL A, V3
[10]  
Johnson Victoria A, 2005, Top HIV Med, V13, P125